Four drugs for injection, such as recombinant human interferon β- 1b, tolvaptan tablets, rapatinib mesylate tablets and fulvestrant injection, were unsuccessful in this update. If the insured starts to use it before 20 19 12 3 1, a transition period of 6 months will be given. After June 30, 2020, the medical and industrial injury insurance funds will no longer pay the drug expenses incurred by the insured. Moreover, designated (agreed) medical institutions in various cities will replace therapeutic drugs in due course.